Sixteen IPD-MAs focused on the evaluation of medical treatments, including antivirals (n = 6) [13, 19, 20, 23, 24, 36], antibodies (n = 4) [14, 15, 34, 40], angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs; n = 2) [16, 38], convalescent plasma (n = 2) [25, 41], COVID-19 vaccines (n = 1) [31], and the Bacillus Calmette–Guérin (BCG)-vaccine (n = 1) [42]. Here, ACE is linked to COVID-19.